Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

Q2040
HCPCS Code

2023 HCPCS
Billable/Valid Code

Q2040 is a valid 2023 HCPCS Code that could be used to indicate Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion for reimbursement purposes.

Q2040 belongs to Medical Care Type of Service and has been in effect since Jan 01, 2019.

Short description for Q2040 HCPCS code:

Tisagenlecleucel car-pos t

HCPCS Q2040

Q2040 code information

HCPCS code:	Q2040
Description:	TISAGENLECLEUCEL, UP TO 250 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION
Effective Date:	Jan 01, 2019
Added Date:	Jan 01, 2018
Termination Date:	HCPCS Q2040 was terminated on Dec 31, 2018
Pricing indicator:	`51` - DRUGS
Multi Pricing indicator:	`A` - NOT APPLICABLE AS HCPCS PRICED UNDER ONE METHODOLOGY
Coverage code:	`C` - CARRIER JUDGMENT
BETOS code:	`O1E` - OTHER DRUGS
Action code:	`N` - NO MAINTENANCE FOR THIS CODE
Type of Service:	`1` - MEDICAL CARE
Anesthesia BUQ:	0